ReviewFrontiers in immunology2023
The bladder cancer immune micro-environment in the context of response to immune checkpoint inhibition.
Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Bladder cancer precision-cut tumor slices (PCTS) preserve functional immune microenvironment enabling ex vivo drug evaluation.BMC medicine · 2026Article
- Machine learning-based identification of basement membrane-related signature to predict recurrence and immunotherapy benefit in bladder cancer.Immunologic research · 2026Article
- CD39/CD73-mediated immunosuppression and tumor aggressiveness in bladder cancer.Cancer immunology, immunotherapy : CII · 2026Article
- The opportunities and barriers for developing tumour-infiltrating lymphocyte therapy for patients with advanced genitourinary cancers.Nature reviews. Urology · 2026Review
- Immunological profile of the tumor immune microenvironment of upper tract urothelial carcinoma predicts recurrence patterns.Cancer immunology, immunotherapy : CII · 2026Article
- Efficacy and mechanisms of immune checkpoint inhibitors in late-stage EGFR-mutated non-small cell lung cancer following targeted therapy resistance.Frontiers in immunology · 2026Review
- Immunohistochemical Expression of Novel Therapeutic Targets in Squamous Cell Carcinoma of the Bladder.Oncology research · 2026Article
- Recent advances in immunotherapy for bladder cancer: mechanisms, clinical applications, and future perspectives.Frontiers in oncology · 2026Review
- Immune landscape of muscle-invasive bladder cancer: role of TIGIT, LAG-3, and PD-L1.Frontiers in immunology · 2026Article
- The Emerging Role of B Cells and Tertiary Lymphoid Structures in Bladder Cancer.Current urology reports · 2025Review
- Multi-omics profiling identifies ESM1 as a key mediator of immunoevasion through the SPP1 pathway in bladder cancer.Scientific reports · 2025Article
- Construction of a gene-metabolite-microbiome regulatory network reveals novel therapeutic targets in bladder cancer through multi-omics analysis.Annals of medicine · 2025Article
- The role of cisplatin in modulating the tumor immune microenvironment and its combination therapy strategies: a new approach to enhance anti-tumor efficacy.Annals of medicine · 2025Review
- Tumor immune microenvironment and immune phenotypes in PD-L1-tested canine urothelial carcinoma.BMC veterinary research · 2025Article
- Comprehensive analysis of coagulation-associated gene signature in bladder cancer diagnosis, prognosis, and immunotherapy.Scientific reports · 2025Article
- Circular RNAs: driving forces behind chemoresistance and immune evasion in bladder cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Unveiling new therapeutic targets for esophageal cancer treatment through single-cell transcriptomics: pH-responsive nanobubbles enhance the efficacy of 125I radiotherapy.Journal of nanobiotechnology · 2025Article
- From Bench to Bladder: The Rise in Immune Checkpoint Inhibition in the Treatment of Non-Muscle Invasive Bladder Cancer.Cancers · 2025Review
- Disulfidptosis related immune genes drive prognostic model development and tumor microenvironment characterization in bladder urothelial carcinoma.Scientific reports · 2025Article
- Chimeric switch and inverted cytokine receptors in T cell therapy: reprogramming T cells to overcome immune suppression in the solid tumor microenvironment.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment with neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy is the default treatment for muscle-invasive bladder cancer (BC). However, with the encouraging results of immune checkpoint inhibitiors (ICI) directed against PD-1/PD-L1 and CTLA-4 in recent years, the treatment landscape of BC is rapidly changing. In addition, it is becoming clear that the effect of ICI is highly dependent on the interaction between tumor cells and the tumor immune micro-environment (TIME). Different immune cells are involved in an anti-tumor response in BC. Cytotoxic CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.